Dr Reddy's Laboratories said its formulations plant in Andhra Pradesh received the Establishment Inspection Report (EIR) from the US drug regulator.
Dr Reddy's Laboratories said that its Formulations Srikakulum Plant (SEZ) Unit I in Andhra Pradesh received the establishment inspection report (EIR) from US Food and Drug Administration (USFDA), indicating closure of the audit. The inspection classification of this facility is determined as "No Action Indicated" (NAI). The announcement was made during market hours today, 13 May 2020.On a consolidated basis, Dr Reddy's Laboratories reported a net loss of Rs 538.40 crore in Q3 December 2019 compared with a net profit of Rs 500.30 crore in Q3 December 2018. Net sales rose 13.86% to Rs 4,383.80 crore in Q3 December 2019 over Q3 December 2018.
Dr Reddy's Laboratories is engaged in providing medicines. The firm operates in three segments: global generics, pharmaceutical services and active ingredients (PSAI) and proprietary products.
Shares of the drug major were up 0.07% to Rs 3,774.75.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
